Literature DB >> 19710021

RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR.

Ann M Toth1, Zhiqun Li, Roberto Cattaneo, Charles E Samuel.   

Abstract

ADAR1 (adenosine deaminase acting on RNA) catalyzes the conversion of adenosine to inosine, a process known as A-to-I editing. Extensive A-to-I editing has been described in viral RNAs isolated from the brains of patients persistently infected with measles virus, although the precise role of ADAR during measles virus infection remains unknown. We generated human HeLa cells stably deficient in ADAR1 ("ADAR1(kd) cells") through short hairpin RNA-mediated knockdown, and using these cells, we tested the effect of ADAR1 deficiency on measles virus (MVvac strain) growth and virus-induced cell death. We found that the growth of mutant viruses lacking expression of the viral accessory proteins V and C (V(ko) and C(ko), respectively) was decreased in ADAR1-deficient cells compared with ADAR1-sufficient cells. In addition, apoptosis was enhanced in ADAR1-deficient cells following infection with wild type and V(ko) virus but not following infection with C(ko) virus or treatment with tumor necrosis factor-alpha or staurosporine. Furthermore, in C(ko)-infected ADAR1-sufficient cells when ADAR1 did not protect against apoptosis, caspase cleavage of the ADAR1 p150 protein was detected. Finally, enhanced apoptosis in ADAR1(kd) cells following infection with wild type and V(ko) virus correlated with enhanced activation of PKR kinase and interferon regulatory factor IRF-3. Taken together, these results demonstrate that ADAR1 is a proviral, antiapoptotic host factor in the context of measles virus infection and suggest that the antiapoptotic activity of ADAR1 is achieved through suppression of activation of proapoptotic and double-stranded RNA-dependent activities, as exemplified by PKR and IRF-3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710021      PMCID: PMC2785566          DOI: 10.1074/jbc.M109.045146

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1.

Authors:  Y Liu; R B Emeson; C E Samuel
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

2.  Modulation of microRNA processing and expression through RNA editing by ADAR deaminases.

Authors:  Weidong Yang; Thimmaiah P Chendrimada; Qingde Wang; Miyoko Higuchi; Peter H Seeburg; Ramin Shiekhattar; Kazuko Nishikura
Journal:  Nat Struct Mol Biol       Date:  2005-12-20       Impact factor: 15.369

3.  Mutated and hypermutated genes of persistent measles viruses which caused lethal human brain diseases.

Authors:  R Cattaneo; A Schmid; P Spielhofer; K Kaelin; K Baczko; V ter Meulen; J Pardowitz; S Flanagan; B K Rima; S A Udem
Journal:  Virology       Date:  1989-12       Impact factor: 3.616

4.  Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible.

Authors:  C X George; C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 5.  Biased (A-->I) hypermutation of animal RNA virus genomes.

Authors:  R Cattaneo
Journal:  Curr Opin Genet Dev       Date:  1994-12       Impact factor: 5.578

6.  Identification of naturally occurring amino acid variations that affect the ability of the measles virus C protein to regulate genome replication and transcription.

Authors:  Bettina Bankamp; Jenna Wilson; William J Bellini; Paul A Rota
Journal:  Virology       Date:  2005-05-25       Impact factor: 3.616

7.  New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1.

Authors:  Deborah R Taylor; Montserrat Puig; Miriam E R Darnell; Kathleen Mihalik; Stephen M Feinstone
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons.

Authors:  J B Patterson; D C Thomis; S L Hans; C E Samuel
Journal:  Virology       Date:  1995-07-10       Impact factor: 3.616

9.  Clonal expansion of hypermutated measles virus in a SSPE brain.

Authors:  K Baczko; J Lampe; U G Liebert; U Brinckmann; V ter Meulen; I Pardowitz; H Budka; S L Cosby; S Isserte; B K Rima
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

10.  Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing.

Authors:  U Kim; Y Wang; T Sanford; Y Zeng; K Nishikura
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

View more
  73 in total

1.  Host response to polyomavirus infection is modulated by RNA adenosine deaminase ADAR1 but not by ADAR2.

Authors:  Cyril X George; Charles E Samuel
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Substitutional A-to-I RNA editing.

Authors:  Bjorn-Erik Wulff; Kazuko Nishikura
Journal:  Wiley Interdiscip Rev RNA       Date:  2010 Jul-Aug       Impact factor: 9.957

3.  Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus.

Authors:  Zhiqun Li; Kristina M Okonski; Charles E Samuel
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 4.  Current strategies for Site-Directed RNA Editing using ADARs.

Authors:  Maria Fernanda Montiel-Gonzalez; Juan Felipe Diaz Quiroz; Joshua J C Rosenthal
Journal:  Methods       Date:  2018-11-29       Impact factor: 3.608

Review 5.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 6.  Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase.

Authors:  Jean-François Gélinas; Guerline Clerzius; Eileen Shaw; Anne Gatignol
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

Review 7.  ADARs: viruses and innate immunity.

Authors:  Charles E Samuel
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 8.  Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Authors:  Denis Gerlier; Douglas S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

9.  Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease.

Authors:  Gillian I Rice; Naoki Kitabayashi; Magalie Barth; Tracy A Briggs; Annabel C E Burton; Maria Luisa Carpanelli; Alfredo M Cerisola; Cindy Colson; Russell C Dale; Federica Rachele Danti; Niklas Darin; Begoña De Azua; Valentina De Giorgis; Christian G L De Goede; Isabelle Desguerre; Corinne De Laet; Atieh Eslahi; Michael C Fahey; Penny Fallon; Alex Fay; Elisa Fazzi; Mark P Gorman; Nirmala Rani Gowrinathan; Marie Hully; Manju A Kurian; Nicolas Leboucq; Jean-Pierre S-M Lin; Matthew A Lines; Soe S Mar; Reza Maroofian; Laura Martí-Sanchez; Gary McCullagh; Majid Mojarrad; Vinodh Narayanan; Simona Orcesi; Juan Dario Ortigoza-Escobar; Belén Pérez-Dueñas; Florence Petit; Keri M Ramsey; Magnhild Rasmussen; François Rivier; Pilar Rodríguez-Pombo; Agathe Roubertie; Tommy I Stödberg; Mehran Beiraghi Toosi; Annick Toutain; Florence Uettwiller; Nicole Ulrick; Adeline Vanderver; Amy Waldman; John H Livingston; Yanick J Crow
Journal:  Neuropediatrics       Date:  2017-04-10       Impact factor: 1.947

10.  Regulation of Human Endonuclease V Activity and Relocalization to Cytoplasmic Stress Granules.

Authors:  Meh Sameen Nawaz; Erik Sebastian Vik; Natalia Berges; Cathrine Fladeby; Magnar Bjørås; Bjørn Dalhus; Ingrun Alseth
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.